Trials / Recruiting
RecruitingNCT06062927
Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
Geno-radiomics Based Model for Response and Prognostic Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, a new post-processing image technology - radiomics is used to screen out parameters of CT and MRI images, which could effectively evaluate the efficacy and prognosis of immunotherapy plus targeted therapy for soft tissue sarcoma (STS). A reliable and effective model for predicting the prognosis of STS will be established based on the radiomic parameters combined with traditional imaging, histophiological, whole exome sequencing (WES) results, inflammatory indicators and changes in the number and function of lymphocyte subsets before and after medication. Patients with advanced STS who may benefit from the combination therapy can be found out by this model.
Conditions
Timeline
- Start date
- 2023-02-02
- Primary completion
- 2026-02-02
- Completion
- 2027-02-02
- First posted
- 2023-10-02
- Last updated
- 2023-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06062927. Inclusion in this directory is not an endorsement.